Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
Compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C 1 -C 10 alkyl) or S; each X is independently CH or N; R 1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R 2 is (LQ) m Y; and each R 3 is independently H, C 1 -C 10 alkyl, aryl or heteroaryl, are surprisingly found to be inhibitors of PI3K-p110δ, and therefore have utility in therapy.
1. A compound represented by formula I:
or a pharmaceutically acceptable salt thereof, wherein:
W is O;
X is CH;
R 2 is (LQ) m Y;
m is 1;
L is C 1 alkylene:
Q is selected from the group consisting of: a direct bond, —NR 3 —, and a heterocyclic linker;
Y is selected from the group consisting of: H, C 1-10 alkyl, —OR 3 , and —C(O)N(R 3 ) 2 ; and
R 3 is independently selected for each occurrence from H or C 1 -C 10 alkyl.
2. The compound of claim 1 , wherein both of the R 3 groups that are attached to the 6,5-ring system in formula I are H.
3. The compound of claim 1 , wherein Q is a heterocyclic linker and Y is H.
4. A compound represented by:
or a pharmaceutically acceptable salt thereof, wherein:
W is O;
X is CH;
R 2 is (LQ) m Y;
m is 1;
L is C 1 alkylene;
Q is NR 3 ;
Y is heterocycle; and
R 3 is independently selected for each occurrence from H or C 1 -C 10 alkyl.
5. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.